Novo Nordisk (NVO) has released an update. Novo Nordisk has disclosed recent transactions involving the purchase of 1,300 American Depositary Receipts (ADRs) by its board members and executives. This ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

Novo Nordisk (NVO) has released an update. Novo Nordisk has announced recent transactions involving its shares by board members and executives, highlighting an acquisition of 18,634 shares and a sale ...

LONDON, Nov 6 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said ... its Phase 3 trial to reflect this higher weight loss. "No change in our confidence level," he said. Analysts view this ...

Novo Nordisk's blockbuster drugs Ozempic and Wegovy have slimmed down Hollywood stars and millions of non-celebrities worldwide — all while adding great heft to Denmark's economy. Novo Nordisk ...

James Manning / PA Images / Getty Images After rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its third-quarter sales fell short of ...

This week, 60 Minutes traveled to Denmark to report on Novo Nordisk, the pharmaceutical company that's behind the popular drugs Wegovy and Ozempic. Novo Nordisk's success with these drugs has led ...

Novo Nordisk was a pioneer in developing GLP-1 drugs for metabolic disorders, but its products are still mainly once-weekly injections. The Danish pharmaceutical giant is putting up $285 million ...

Novo Nordisk and Ascendis Pharma have agreed to collaborate in developing metabolic and cardiovascular therapies, among them a once-monthly glucagon-like peptide receptor agonist (GLP-1RA).